

## Tumor- Infiltrating Lymphocytes (TILs) as a Prognostic Factor in Female Patients with Invasive Breast Carcinoma

Dr. Safaa Qatleesh<sup>1</sup> , Prof. Ayman Sammoun<sup>2</sup>, Prof. Eyad M Chatty<sup>3</sup>

<sup>1,2,3</sup> Pathology Department, Faculty of Medicine, Damascus University, Syria

Dr.Safaa Qatleesh : [safaa\\_100@yahoo.com](mailto:safaa_100@yahoo.com)

### Abstract

**Background:** Breast cancer is a major public health problem for woman. Several studies suggested that development and progression of malignant tumors are characterized by an interaction with the cells in the tumor microenvironment including infiltrating immune cells.

**Aim:** The aim was to investigate relationship between tumor infiltrating lymphocytes (TILs) in infiltrating breast carcinoma and other recognized clinicopathological factors.

**Material and Methods:** 100 cases of infiltrating breast carcinomas were included in the study. Stromal TILs status was evaluated using hematoxylin and eosin staining. For all statistical data chi-square test was applied using SPSS and Spearman correlation. P-values of less than 0.05 were considered as significant.

**Results:** Stromal TILs correlated with well-established prognostic markers: HER2 positivity (P=0.001), higher tumour grade (P=0.016), ER negativity (P=0.015), PR negativity (P=0.008), lymph node status (P=0.005) and lymphovascular invasion (LVI) (P=0.001), molecular classification (P=0.000), and p53 positivity (P=0.013). No correlation between CD10 positivity or high proliferative index (KI67) and stromal TILs.

**Conclusion:** Stromal TILs is directly correlated more aggressive phenotype: HER2 positivity, ER negativity, PR negativity, molecular classification, present LVI, higher tumor grade and greater nodal involvement; so TILs could be used as novel predictive and prognostic parameter and used to develop newer drugs (immunotherapy).

**Keywords:** TILs, Breast Carcinoma, Stroma, Prognosis.

### 1.Introduction:

Infiltrating Breast carcinoma is the most common non-skin malignancy in women. <sup>[1,2]</sup> Breast tissue is composed of glandular formations (epithelial component) and stroma (mesenchymal component). Epithelial growth of tumor depends partly on chemical factors between both components (tumor and stroma). <sup>[3]</sup> Infiltrating breast carcinoma is a malignant tumour arising in the epithelial cells of the terminal ductal lobular unit (TDLUs), stromal tumor microenvironment (TME) plays a very important role in breast cancer tumor progression, evolution, invasion and metastasis, also tissue microenvironment plays a key role in controlling cell migration, survival, proliferation, polarization, and differentiation. <sup>[4,5]</sup> A better understanding of stromal participation to cancer progression will identify specific pathways and signals that motivate dedifferentiation, growth, invasion of malignant cells and may eventually result in the determination and identification of novel therapeutic agents for future treatment. <sup>[6]</sup> Stromal markers are now emerging as new novel factors to estimate the prognosis of infiltrating breast cancer. Development and progression of malignant proliferations are characterized by an interaction with

the cells in the tumor microenvironment including infiltrating immune cells.<sup>[7]</sup>

In immune cell infiltration in breast cancer tissue, the expression of tumour-related immune cells differed greatly among different breast cancer subtypes and patients.<sup>[8]</sup> Lymphocyte-predominant breast cancer (LPBC) is defined as a presentation wherein at least 50% of the tumour tissue is invaded by tumour-infiltrating lymphocytes (TILs), TIL expression could serve as a strong prognostic marker for colorectal and breast cancer, thereafter, many retrospective studies reported that TIL expression in breast cancer could predict the efficacy of drug therapy and prognosis.<sup>[9,10]</sup>

Although the methods to quantify TIL expression and cut-off TIL values in breast cancer tissues varied among studies and have not been clearly standardized, the International TILs Working Group published the first guidelines for a TIL evaluation in 2014<sup>[11]</sup>.

Accordingly, mononuclear immune cells located between tumor sheets, i.e., within the tumor stroma, are defined as stromal TILs (str-TILs).

The International Working Group recommended that str-TIL expression should be graded as :

- low (str-TILs: <10%).
- Intermediate (str-TILs:  $\geq 10$  and  $\leq 40\%$ ).
- High (str-TILs: >40%) .

TIL expression should be graded based on their relative abundance within the tumor stroma.<sup>[11]</sup>

The extent of TILs in IBC is gaining importance as a prognostic marker, for quantifying TILs, it is recommended to follow the scoring recommendations (steps) according to WHO classification of breast tumors 2019.<sup>[12]</sup>

The steps are:

1-Define the area for evaluation Large areas of central necrosis or fibrosis are not included in the evaluation.

2-Focus only on stromal TILs.

3-Determined the type of inflammatory infiltrate include only mononuclear infiltrate (lymphocytes and plasma cells).

4 & 5: Assess and report the percentage of the stromal area involved by TILs, report the average of the stromal area; do not focus on hotspots.<sup>[12]</sup>

## 2.Aim and Objectives:

The aim was to investigate relationship between tumor infiltrating lymphocytes (TILs) in infiltrating breast carcinoma other recognized clinicopathological factors .

## 3.Materials and Methods:

This study was performed on 100 women who had undergone modified radical mastectomy for infiltrating breast carcinoma in Al-Assad University Hospital (Damascus ,Syria) during 2017. None of the patients had received neoadjuvant therapy. Tissue from primary tumor was processed, paraffin blocks were prepared and six slides were cut from each:

Slide 1: Stained with hematoxylin and eosin.

Slide 2: Immunohistochemistry for estrogen receptor

Slide 3: Immunohistochemistry for progesterone receptor.

Slide 4: Immunohistochemistry for HER2/neu

Slide 5: Immunohistochemistry for CD10

Slide 6: Immunohistochemistry for KI67 .

Hematoxylin and-eosin stained microscopic slides of the primary mass were reviewed to complete the study, evaluation of stromal TILs ,define tumor subtype, and perform grading of

infiltrating carcinomas according to the Nottingham modification of the Bloom and Richardson system.<sup>[12]</sup> **Tumor size** in this study means the greatest tumor diameter in millimeter. **Lymph node status** was defined according to tumor node metastasis (TNM) staging system for breast carcinoma in which 0 correspond negative nodes, 1-3 positive nodes (N1), 4-9 positive nodes (N2), and 10 or more positive nodes (N3), respectively. **Estrogen receptor (ER) and progesterone receptor (PR) markers** were considered as positive when at least 1% of tumor cell nuclei were immunoreactive for the marker.<sup>[12]</sup> **Expression of human epidermal growth factor receptor 2 (HER2/neu)** was scored as 0 to 3 as Follow: Score of 0 (negative): no staining or membrane staining in less than 10% of the tumor cells, 1+ (negative): a faint/barely perceptible partial staining in the membrane of more than 10% of the tumor cells, 2+ (weakly positive): a weak to moderate complete membrane staining in more than 10% of the tumor cells, and 3+ (strongly positive) : a strong complete membrane staining in more than 30% of the tumor cells.<sup>[13]</sup>

#### 4. Study Design : systematic reviews and meta-analysis

**5. Ethics:** Our study was performed on paraffin blocks of tumor tissue. No tests, measurements or experiments were performed on humans as apart of this work.

**6. Statistics:** We used well-known prognostic biomarkers, such as ER, PR, and HER2/neu, as well as clinicopathological prognostic factors including: grade, lymph node status, CD10 expression, p53 and molecular classification to investigate the prognostic potential of stromal TILs in breast carcinoma.

The collected data was analyzed using SPSS. The relationships between stromal TILs and all variables were evaluated by Chi-square. P-values of less than 0.05 were considered as significant.

#### 7. Results:

100 cases of infiltrating breast carcinoma were included in this study. Age of the patients ranged from 33-79 years, the majority were in 5th decade. The size of the tumors ranged from 11 to more than 50 mm and the tumor size was more than 50 mm in 48% of cases. Infiltrating ductal carcinoma, no special type (NST) comprised the majority of our study population (60 cases, 60%), followed by 30 cases (30%) of invasive lobular carcinoma (ILC), 4 cases (4%) of micropapillary carcinoma, 4 cases (4%) of invasive cribriform carcinoma and 2 cases (2%) of tubular carcinoma. All cases of invasive breast carcinoma were graded based on the Bloom and Richardson grading system. Most cases (56 cases, 56%) were grade II, followed by 30 (30%) grade III, and 14 (14%) grade I cases. Regarding the lymph node status, 44 cases (44%) lacked lymph node involvement.

Stromal TILs evaluated according to WHO classification 2019.<sup>[2]</sup>


CD10 immunostaining was performed on all 100 cases. No stromal expression was detected in the normal tissue of breast. The myoepithelial cells lining the normal TDLUs components in normal breast parenchyma adjacent to the tumor were considered as the positive control for CD10 expression.

The staining was scored as negative, weak, and strong as described previously in the methods section. CD10 was found to be positive in 60% (60 cases), out of which 28% (28 cases) showed weak immunoreactivity and 32% (32 cases) showed strong immunoreactivity. Most patients in this study were ER positive (74 cases, 74%) and PR positive (72 cases, 72%).

Stromal TILs correlated with well-established prognostic markers: HER2 positivity ( $P=0.001$ ) higher tumour grade ( $P=0.016$ ), ER negativity ( $P=0.015$ ), PR negativity ( $P=0.008$ ), lymph node involvement ( $P=0.005$ ) and lymphovascular invasion

(LVI) ( $P=0.001$ ), molecular classification ( $P=0.000$ ), and p53 positivity ( $P=0.013$ ).


Chi-square test showed a statistically significant correlation between stromal TILs and ER negativity ( $P = 0.015$ ), the same finding was observed about PR negativity ( $P = 0.008$ ) (Figures 1,2).



A statistically significant positive association was seen between stromal TILs and lymph node status ( $P=0.005$ ), a higher percent in TILs was seen in cases with lymph node metastases (N3: 10 lymph nodes or more 46%).

A statistically significant positive association was seen between stromal TILs and Lymphovascular invasion (LVI); high grade TILs was seen in cases with lymphovascular invasion (100%) (Figure 3).


A statistically significant positive association was seen between stromal TILs and tumor grade; a higher percent high grade TILs was seen in cases classified grade III (40%)(Figure 4)




No statistically significant positive association was seen between stromal TILs and stromal CD10 positivity ( $P=0.071$ ).

No statistically significant positive association was seen between stromal TILs and proliferative index KI67 ( $P=0.136$ ).

A statistically significant association was seen between stromal TILs and molecular classification ( $P=0.000$ ), a higher percent in high grade TILs was seen in luminal B (HER2-positive) (100%), followed by HER2 positive(non-luminal)( 40%) and triple negative (25%)(Figure 5).



Figure(5): TILs and molecular classification



**Figure(6) A+B :Stromal TILs in breast carcinoma(mononuclear cells composed of lymphocytes and plasma cells) in our study , C: Nuclear staining of tumor cells for p53 by IHC stain.**

## **8.Discussion:**

Development and progression of malignant tumors are characterized by an interaction with the cells in the tumor microenvironment including infiltrating immune cells.<sup>[7]</sup>

In immune cell infiltration in breast cancer tissue, the expression of tumour-related immune cells differed greatly among different breast cancer subtypes and patients.<sup>[8]</sup>

In our study stromal TILs correlated with well-established prognostic markers: HER2 positivity (P=0.001) higher tumour grade (P=0.016), ER negativity (P=0.015).

also the same results found in a study performed by Kurozumi et al in the year 2019<sup>[8]</sup>

In our study no correlation between stromal TILs and KI67 ,whereas Losurdo et al<sup>[14]</sup> study revealed positive correlation between stromal TILs and high proliferative index (KI67).

Our study showed correlation between stromal TILs and lymph node status, also the same results found in a study performed by Losurdo et al in year 2020.<sup>[14]</sup>

Most of the results are similar may be due to the similarity of descriptive statistics between studies.

## **9.Conclusion:**

TILs could be used as novel prognostic and predictive factor.

Our findings support the use of stromal TILs to identify a more aggressive phenotype of tumors.

A further study to validate the prognostic utility of TILs based on breast cancer subtypes in large cohorts is required.

PD-L1(Programmed death-ligand 1) recommended for prognosis and identifying breast carcinoma patients who benefit most from immunotherapy by PDL1 inhibition because the results from the current meta-analysis support integrating immunotherapy with conventional in future breast carcinoma research.

Further studies are needed including larger number of patients to identify the effect between TILs and chemotherapy response.

## **10.Conflict of interest**

The authors declare that they have no potential conflicts of interest to disclose.

## **11.Funding Statement:**Not available

## **12.References:**

- 1.Swayamprava Pradhan, Chandan Bajad, Debi Prasad Mishra.Stromal expression of CD10 in invasive breast carcinoma and its correlation with known prognostic markers. J. Evid. Based Med. Healthc. 2017.
2. WHO Classification of Tumours of the Breast. Sunil R. Lakhani Ian O. Ellis Stuart J. Schnitt Puay Hoon Tan Marc J. van de Vijver. IARC ,2019.
3. Makretsoy NA, Hayes M, Carter BA. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol

2007; 20(1): 84-9.

4. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. *Curr Opin Cell Biol* 2004;16(5):558-564.
5. Fidler IJ. The pathogenesis of cancer metastasis: the seed and soil hypothesis revisited. *Nature Reviews Cancer* ,2003;3(6):453-458.
6. O. De Wever, M. Mareel. Role of tissue stroma in cancer cell invasion. *Journal of Pathology*, 2003; 200(4): 429–447.
7. S.E. Stanton, S. Adams, M.L. Disis. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. *JAMA Oncol.* 2 (10) (2016) 1354–1360.
8. Sasagu Kurozumi ,Hiroshi Matsumoto. Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis. *ONCOLOGY LETTERS* 17: 2647-2656, 2019.
9. Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer-a substudy of the neoadjuvant Gepar Quinto trial. *PLoS One* 8: e79775, 2013.
10. Denkert C, von Minckwitz G, Brase JC. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. *J Clin Oncol* 33: 983-991, 2015.
11. Salgado R, Denkert C, Demaria S, Sirtaine N. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. *Ann Oncol* 26: 259-271, 2014.
12. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of stromal microenvironment in carcinogenesis. *Int J Cancer*. 2003;107(1):1-10.
13. Rosai and Ackerman's surgical pathology. Eleventh edition. Philadelphia, PA: Elsevier; 2018.
14. Agnese Losurdo, Rita De Sanctis, Bethania Fernandes . Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice. *Scientific Reports* . (2020) 10:20100.